CHF Solutions, Inc. (CHFS) Reached 52 Week Low at $1.85

June 29, 2018 - By Gwen Gough

CHF Solutions, Inc. (NASDAQ:CHFS) hit 52 week low with $1.70 target or 8.00 % below the last $1.85 stock price. Barchart.com published the 52 week low on Jun, 29. It has $8.33M market cap. At our $1.70 target, the company worth will be $666,240 less.

Ticker’s shares touched $1.85 during the last trading session after 11.90% change.CHF Solutions, Inc. has 392,140 shares volume, 29.62% up from normal. CHFS is downtrending and has moved 75.43% since June 29, 2017. CHFS underperformed by 88.00% the S&P 500.

For more CHF Solutions, Inc. (NASDAQ:CHFS) news published recently go to: Benzinga.com, Benzinga.com, Benzinga.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “25 Stocks Moving In Friday’s Pre-Market Session” published on June 15, 2018, “54 Biggest Movers From Yesterday” on June 27, 2018, “40 Stocks Moving In Tuesday’s Mid-Day Session” with a publish date: June 26, 2018, “CHF Solutions, Inc. Hires Additional Field Sales Representatives and Expands Territories” and the last “CHF Solutions to Exhibit at the 14th Annual American Association of Heart Failure Nurses Meeting” with publication date: June 06, 2018.

CHF Solutions, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States.The company has $8.33 million market cap. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.Last it reported negative earnings. The firm was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: